World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
43664
World Ranking
8813
National Ranking
4540

Mark C. Genovese publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark C. Genovese sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 481 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark C. Genovese D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark C. Genovese sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark C. Genovese is an active researcher affiliated with Stanford University in the United States. Their work focuses predominantly on the field of medicine, with a strong emphasis on rheumatology, genetics, pathology and forensic medicine, hematology, and immunology.

The researcher has contributed extensively to the study of rheumatoid arthritis, chronic lymphocytic leukemia, lymphoma diagnosis and treatment, autoimmune and inflammatory disorders, biosimilars and bioanalytical methods, systemic lupus erythematosus, and chronic myeloid leukemia treatments.

Some of their recent publications include:

  • Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study (2020, The Lancet Rheumatology)
  • Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (2020, Arthritis & Rheumatology)
  • Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial (2021, Annals of the Rheumatic Diseases)
  • 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2021, Arthritis Care & Research)
  • 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2021, Arthritis & Rheumatology)

Mark C. Genovese frequently collaborates with other researchers in the field. Frequent co-authors include:

  • Kevin Winthrop
  • Tsutomu Takeuchi
  • Gerd R Burmester
  • R. Besuyen
  • Beatrix Bartók

Their work appears regularly in several leading publication venues, demonstrating a consistent presence in the academic community. These venues include:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • Arthritis & Rheumatology
  • The Lancet Rheumatology
  • Arthritis Research & Therapy

Best Publications

  • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

    Stanley B Cohen;Paul Emery;Maria W Greenwald;Maxime Dougados

  • A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

    Joan M. Bathon;Richard W. Martin;Roy M. Fleischmann;John R. Tesser

  • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

    Mark C Genovese;Jean-Claude Becker;Michael Schiff;Michael Luggen

  • 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

    Liana Fraenkel;Joan M Bathon;Bryant R England;E William St Clair

  • Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

    Mark C. Genovese;James D. McKay;Evgeny L. Nasonov;Eduardo F. Mysler

  • Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study

    Graeme Jones;Anthony Sebba;Jieruo Gu;Mitchell B Lowenstein

  • Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

    Mark C. Genovese;Joan M. Bathon;Richard W. Martin;Roy M. Fleischmann

  • Autoantigen microarrays for multiplex characterization of autoantibody responses

    William H. Robinson;Carla DiGennaro;Wolfgang Hueber;Brian B. Haab

  • Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

    Mark C. Genovese;Stanley Cohen;Larry Moreland;Deborah Lium

  • Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

    Edward C. Keystone;Mark C. Genovese;Lars Klareskog;Elizabeth C. Hsia

  • Baricitinib in Patients with Refractory Rheumatoid Arthritis

    Mark C. Genovese;Joel Kremer;Omid Zamani;Charles Ludivico

  • LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis a phase I randomized, double-blind, placebo-controlled, proof-of-concept study

    M. C. Genovese;F. Van den Bosch;S. A. Roberson;S. Bojin

  • Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity.

    Eric J. Kunkel;James J. Campbell;Guttorm Haraldsen;Junliang Pan

  • Rules of chemokine receptor association with T cell polarization in vivo

    Chang H. Kim;Lusijah Rott;Eric J. Kunkel;Mark C. Genovese

  • An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

    Michael E. Weinblatt;Arthur Kavanaugh;Mark C. Genovese;Theresa K. Musser

  • Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

    Joel M. Kremer;Mark C. Genovese;Grant W. Cannon;Jacques R. Caldwell

  • Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.

    Roy Fleischmann;Maurizio Cutolo;Mark C. Genovese;Eun Bong Lee

  • Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.

    Joel Kremer;Zhan-Guo Li;Stephen Hall;Roy Fleischmann

  • Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

    Philip J. Mease;Mark C. Genovese;Maria W. Greenwald;Christopher T. Ritchlin

  • Bonzo/CXCR6 expression defines type 1–polarized T-cell subsets with extralymphoid tissue homing potential

    Chang H. Kim;Eric J. Kunkel;Judie Boisvert;Brent Johnston

Frequent Co-Authors

Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center
Michael E. Weinblatt
Michael E. Weinblatt Brigham and Women's Hospital
Edward C. Keystone
Edward C. Keystone University of Toronto
Paul Emery
Paul Emery University of Leeds
Joel M. Kremer
Joel M. Kremer Albany Medical Center Hospital
Alan J. Kivitz
Alan J. Kivitz Altoona Arthritis and Osteoporosis Center
Josef S. Smolen
Josef S. Smolen Medical University of Vienna
Gerd R. Burmester
Gerd R. Burmester Charité - University Medicine Berlin
William H. Robinson
William H. Robinson Stanford University
Kevin L. Winthrop
Kevin L. Winthrop Oregon Health & Science University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring career options beyond a traditional MD in the USA? Many students are considering related online degrees that open doors to healthcare leadership, pharmacy, nursing, and informatics roles. Completing your degree online allows for greater flexibility while balancing work or family commitments.

A major consideration for students is the cost of mha degree, particularly as tuition rates can vary widely. For those interested in advanced nursing, there are dnp online programs cheap that offer affordable routes to becoming a Doctor of Nursing Practice without the expense of on-campus study.

Aspiring pharmacists can take advantage of quality online pharmacy school programs to earn their credentials while studying remotely. Additionally, students interested in medical coding, data management, or digital health can enroll in rhit programs online to prepare for careers in health information management.

Overall, these online healthcare degrees provide accessible and cost-effective pathways to rewarding medical and healthcare careers in the USA.

Best Scientists Citing Mark C. Genovese

Trending Scientists

Recently Published Articles